Keymed Biosciences, Inc. (HK:2162)
:2162
Top Page
Keymed Biosciences, Inc.
(2162)
Select Model
Select Model
Rating:41Neutral
Price Target:
HK$52.00
▼(-17.20% Downside)
Action:ReiteratedDate:10/23/25
Keymed Biosciences, Inc. faces significant challenges with ongoing losses and negative cash flows despite revenue growth. The technical indicators suggest bearish momentum, and the valuation is unattractive due to a negative P/E ratio. The company's strong balance sheet is a positive aspect, but the path to profitability remains uncertain.
Positive Factors
Revenue Growth
Sustained multi-year revenue expansion shows durable demand for Keymed's therapies and progress commercializing assets. Strong top-line growth improves funding optionality, strengthens partnership negotiating leverage, and reduces execution risk as the company scales clinical and commercial activities.
Negative Factors
Negative Free Cash Flow
Persistent negative free cash flow and lack of operating cash generation create a structural funding gap. The company will likely need external financing or milestone-based partner payouts to sustain operations, raising dilution risk and constraining strategic flexibility for trials and commercialization investments.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Sustained multi-year revenue expansion shows durable demand for Keymed's therapies and progress commercializing assets. Strong top-line growth improves funding optionality, strengthens partnership negotiating leverage, and reduces execution risk as the company scales clinical and commercial activities.
Read all positive factors
Keymed Biosciences, Inc. (2162) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$18.81B
Dividend YieldN/A
Average Volume (3M)1.75M
Price to Earnings (P/E)―
Beta (1Y)1.02
Revenue Growth964.40%
EPS Growth65.90%
CountryHK
Employees1,258
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.82
Shares Outstanding298,735,570
10 Day Avg. Volume1,976,819
30 Day Avg. Volume1,752,076
Financial Highlights & Ratios
PEG Ratio-0.34
Price to Book (P/B)3.07
Price to Sales (P/S)17.76
P/FCF Ratio-7.57
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$84.57Price Target Upside34.66% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)1.88
Revenue Forecast (FY)HK$1.66B
Keymed Biosciences, Inc. Business Overview & Revenue Model
Company Description
Keymed Biosciences Inc., a biotechnology company, engages in the research and development of biological therapies for the treatment of autoimmunity and oncology diseases. Its lead product candidate is CM310 for the treatment of moderate to severe ...
How the Company Makes Money
Keymed Biosciences, Inc. generates revenue primarily through the development and commercialization of its therapeutic products. The company earns money by entering into strategic partnerships and collaborations with larger pharmaceutical firms, wh...
Keymed Biosciences, Inc. Financial Statement Overview
Summary
Income Statement
35
Negative
Balance Sheet
50
Neutral
Cash Flow
30
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 872.19M | 428.12M | 354.10M | 100.06M | 110.27M | 0.00 |
| Gross Profit | 830.25M | 415.92M | 317.22M | 97.48M | 93.07M | 0.00 |
| EBITDA | -312.61M | -574.46M | -269.77M | -259.25M | -3.86B | -135.09M |
| Net Income | -257.34M | -515.24M | -359.36M | -308.12M | -3.90B | -832.73M |
Balance Sheet | ||||||
| Total Assets | 4.63B | 3.77B | 3.88B | 3.93B | 3.93B | 529.95M |
| Cash, Cash Equivalents and Short-Term Investments | 2.80B | 2.16B | 2.72B | 3.18B | 3.52B | 354.08M |
| Total Debt | 872.30M | 753.24M | 418.71M | 121.97M | 39.26M | 66.86M |
| Total Liabilities | 1.44B | 1.29B | 896.11M | 593.10M | 289.07M | 1.62B |
| Stockholders Equity | 3.19B | 2.47B | 2.99B | 3.34B | 3.65B | -1.09B |
Cash Flow | ||||||
| Free Cash Flow | -854.73M | -1.00B | -686.23M | -681.48M | -387.50M | -139.26M |
| Operating Cash Flow | -604.67M | -789.63M | -303.62M | -401.93M | -214.64M | -119.36M |
| Investing Cash Flow | -92.13M | 67.71M | 468.20M | -645.59M | -2.04B | -113.07M |
| Financing Cash Flow | 905.48M | 283.90M | 72.13M | -8.06M | 3.64B | 7.40M |
Keymed Biosciences, Inc. Technical Analysis
Positive
62.80
Price Trends
54.91
Positive
56.36
Positive
59.76
Positive
Market Momentum
2.22
Negative
73.78
Negative
84.51
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2162, the sentiment is Positive. The current price of 62.8 is above the 20-day moving average (MA) of 54.98, above the 50-day MA of 54.91, and above the 200-day MA of 59.76, indicating a bullish trend. The MACD of 2.22 indicates Negative momentum. The RSI at 73.78 is Negative, neither overbought nor oversold. The STOCH value of 84.51 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2162.
Keymed Biosciences, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | HK$24.33B | 42.36 | 15.32% | ― | 48.38% | ― | |
54 Neutral | HK$17.98B | -22.61 | -12.74% | ― | -76.58% | -4.90% | |
53 Neutral | HK$10.79B | -77.24 | -11.84% | ― | 1219.19% | 25.15% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
41 Neutral | HK$18.81B | -25.84 | -9.08% | ― | 964.40% | 65.90% | |
40 Underperform | HK$11.36B | 30.77 | 24.17% | ― | 240.05% | -140.09% |
* Healthcare Sector Average
HK:2162
Keymed Biosciences, Inc.
67.00
19.00
39.58%
HK:1672
Ascletis Pharma, Inc.
16.94
10.44
160.62%
HK:2096
Simcere Pharmaceutical Group Limited
13.52
5.00
58.69%
HK:2157
Lepu Biopharma Co. Ltd. Class H
6.11
2.13
53.52%
HK:2171
CARsgen Therapeutics Holdings Ltd.
18.67
3.99
27.18%
HK:2315
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
59.55
46.19
345.73%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.